1. Introduction {#sec1}
===============

Type 2 diabetes mellitus (T2DM) can be characterized as a hyperglycaemic, non-infective metabolic disorder that is associated with a dysfunctional β-cell, deficit in insulin secretion as well as a decreased cell response and insulin sensitivity ([@bib14]). The recent edition on diabetes prevalence as reported by the International Diabetes Federation (IDF) estimated the possibility of an increase in the number of diabetes mellitus patients from 424.9 million in 2017 to 628.6 million by 2045 with more than 90 % occupying Type 2 Diabetes Mellitus ([@bib27]). This morbid condition increases the risk of triggering many biochemical pathways that aids both micro and macrovascular complications, with cerebrovascular accidents and insults such as ischemic stroke and brain injury inclusive. Propagation of this disorder can be associated with the delicate vascular, metabolic and endocrine disorientation mediated by diabetes since impaired glucose regulation related to type 2 diabetes mediates various complications, though, their role in cerebral insults and complications seems unclear ([@bib21]). For example, cerebral arteries contain insulin receptors with its vasodilating effect being dependent on the concentration of insulin ([@bib24]). Insulin resistance found in type 2 diabetes mellitus decreases the concentration of nitric oxide (NO) responsible for vasorelaxation, thereby, deregulating the constant cerebral perfusion required by the brain. Also, episodes of hypoglycemia and hyperglycaemic occurrence in diabetes condition has a deletory effect on the cerebral function ([@bib7]).

Increased oxidative stress accompanies cell damage, cell dysfunction, as well as cell death since their generation during hyperglycaemic state, is triggered, thereby exceeding cellular antioxidant defense mechanism. However, treatment of this troubling condition requires not only an agent that proves safety, bioavailability and therapeutic capability but that which will enhance insulin sensitivity and abruptly discontinue pancreatic β-cell failure and possibly address micro and macro-vascular associated complexities. Available therapeutic strategies include the sulfonylureas, Biguanides/metformin, alpha-glucosidase inhibitors, thiazolidinediones, and the meglitinides but studies and data collected from diabetic patients have revealed the potential side effects posed by these common diabetes drugs. This ranges from severe blood glucose reduction (hypoglycemia), risk of liver disease, gastrointestinal diseases, kidney complications, weight gain and many more.

Plant-derived phytomolecules represents the new area of focus in the health industry owing to their unique phytochemistry. Various research have proven their ability to moderate different series of chemical reaction required in the treatment of numerous metabolic conditions such as cancer, diabetes, Kidney diseases, Inflammatory diseases, etc ([@bib42]). Diosgenin (DG) is a phytosteroidal sapogenin that is majorly found in edible pulses and root including roots of wild yam also known as the Dioscoroceae. Efficacy of diosgenin has been explored in various diseases such as Metabolic dysfunction ([@bib53]) where diosgenin displayed critical activity in adipocyte differentiation. In Liver injury, diosgenin has been reported to have undergone a protective role against ethanol-induced liver injury ([@bib55]). Also, the Renoprotective effect of diosgenin ([@bib29]) and protective role against Colorectal cancer ([@bib1]) was also reported. The neuroprotective effect of diosgenin glycosides was recently studied and its selective suppression of inflammatory factors such as IL-6 and NO shows its potential effectiveness in slowing down the development of certain neurodegenerative disorders ([@bib52]).

Various animal models have been used to study disease development and therapeutic potential these include, mice, rats, and rodents but their labor-intensive property has represented its limitation ([@bib56]). Zebrafish (*Danio rerio*) is undergoing wide exploration as an animal model in disease discovery, disease development and drug discovery due to their fertility and unique genetic and physiological similarity as that of mammals ([@bib20]). Various models have been established such as visceral adiposity ([@bib36]), impaired glucose metabolism ([@bib10]), non-alcoholic steatohepatitis ([@bib4]) including diabetes ([@bib30]), using zebrafishes. This study aims at studying the glucose-regulating effect of Diosgenin in an STZ-induced type 2 diabetes Zebrafish model including the possibility of hyperglycemic-mediated cerebral ischemic damage while presenting a mild exploration of DG towards its neuroprotective role against resulting traces of brain injury.

2. Materials and methods {#sec2}
========================

2.1. Collection, experimental design, and maintenance of zebra fishes {#sec2.1}
---------------------------------------------------------------------

The animal protocol was designed to minimize pain or discomfort to zebrafishes. 3--5 cm long adult healthy wild type zebra fishes (*Danio rerio*), Tubingen background of both sexes were procured from a certified supplier in India. The experimental protocol for the development of type 2 diabetes mellitus was approved by the "Institutional Animal Ethics Committee", Amity Institute of Pharmacy, Amity University, Noida, Uttar Pradesh as stated in the guidelines of the "Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA/AIP/2013/004) under chapter 4 section 15, subsection 1 of the prevention of Cruelty to Animals Act 1960 (CPCSEA, Ministry of Environment, Forest and Climatic Change, Government of India, Animal Welfare Division, 5^th^ floor, Vayu Wing, Indira Paryavaran Bhawan Jor Bagh Road, New Delhi-110003. The fishes were housed in our zebra-fish experimental room and acclimatized for 15 days. Fishes were allowed free movement in a 5L tank with a maximum of 15 fishes in each tank at a temperature of 28 ± 2 °C at a pH of 7.0--8.0. Fishes were kept under aeration and a 12h/12h dark and light photocycle was maintained. Fishes were fed twice daily with normal fish meal that comprises soya bean meal, wheat flour and rice flour supplemented with fish and fish derivatives (Toya fish food, India). The water in the tanks was changed every 3days throughout the experiment and the weight and behavioral analysis was also investigated and recorded twice every week. Fishes were randomly selected in this study.

2.2. Drugs and reagents {#sec2.2}
-----------------------

Diosgenin was procured from Chromadex, Irvine, CA 92618 USA and stored at room temperature for further use. Previously extracted BG oil was used as the drug solubilizing agent in this study. Streptozotocin (STZ) was procured from Sisco Research Laboratories Pvt Ltd, Maharashtra, India and stored at 4 °C for further use. Glucose test kit was procured from Transasia Biochemical limited, Solan and was also stored between 2-8 °C. All other chemicals and reagents used in this study were of analytical grade.

2.3. Induction of diabetes {#sec2.3}
--------------------------

A stock of 1 mg/mL STZ solution was prepared in 0.85 % normal saline. Fishes were grouped into Control (n = 10) and Disease (n = 36). The diseased group were distributed into different 5L capacity tanks with 12 fishes distributed in each. STZ was administered through the tail vein of the zebrafishes. A multi-low dose of 20 mg/kg b*.w* of streptozotocin was intravenously administered to ZF with a 1mL syringe having a 1-inch needle at a 7-day interval for a period of 28 days. At every 7^th^ day, fishes were collected and sacrificed by placing on ice to initiate hypothermia. The liver and brain tissues were collected and stored appropriately for biochemical and histopathological analysis. Signs of stress and anxiety were observed by carrying out the behavioral changes in fishes. Weight of fishes with disease progression was also studied continuously throughout the study.

2.4. Experimental treatment procedure {#sec2.4}
-------------------------------------

Diseased fishes were further divided into four groups: Positive standard control (n = 5), DG 1 treated group (n = 5), DG2 treated group (n = 6) and BG (n = 6). The positive standard control received 500mg metformin while the treated group received 20 and 40mg/BW DG respectively, while 5μL oil was administered to the BG group. Treatment with DG and Metformin commences after 28 days of induction of diabetes. 1mg DG was weighed and allowed to dissolve in BG oil. Dose of each respective drug was administered at every 3^rd^ day for a period of 28 days. After each 7^th^ day, fishes were collected and sacrificed for biochemical and histopathological analysis.

The study group is as indicated below.•Group 1 - Normal Control (Naked)•Group 2 - Negative Control (n = 6) STZ•Group 3 - Vehicle (n = 6) BG Vehicle (5 μL)•Group 4 - Positive Control (n = 6) 500 mg/kg Metformin•Group 4--20 mg/kg DG (ip)•Group 5--40 mg/kg DG (ip)

At the end of the study, blood glucose level, weight and behavioral pattern, including the catalytic activity of the fishes were studied.

2.5. Determination of blood glucose {#sec2.5}
-----------------------------------

The blood glucose of STZ and DG treated fishes was determined by using the GOD-POD endpoint method ([@bib50]). On the night of each 7^th^ day, fishes were left unfed over the night against sacrifice on the following day. Fishes were sacrificed by placing on ice until they become completely still. Tissue samples were removed and stored at -20 °C in phosphate-buffered saline (PBS) of pH 7.4. Tissues stored were collected from storage and homogenized with a manual crusher. The resulting homogenized tissue solution was centrifuged at 14,000 rpm for 15 min. Post mitochondrial Supernatant (PMS) was collected and used for the analysis. The concentration of glucose was determined spectrometrically using the Malvern UV-Visible Spectrophotometer and absorbance was recorded at 505 nm. The concentration of glucose in mg/dL of control and diseased samples was calculated as shown.$$\text{Glucose~(mg/dL)~} = \ \frac{\text{Absorbance~of~test}}{\text{Absorbance~of~standard}} \times \text{Concentration\ of\ standard\ (mg/dL)}$$

Concentration above 100 mg/dL and 125 mg/dl is taken as the onset and diabetes establishment respectively as STZ dosing progresses till the 28^th^ day.

2.6. Catalytic activity {#sec2.6}
-----------------------

The catalase activity was measured according to the method described by [@bib13] ([@bib13]). Briefly, 1.99 mL of 0.05M phosphate buffer (pH 7) was introduced into each well-labeled control and test tubes in duplicates. Subsequently, 10μL PMS was added and 1mL of freshly prepared 20mM H~2~O~2~ was added. Absorbance was recorded at 340 nm kinetically for 120 s. The activity of oxidant defense and enzymes in each sample was calculated as shown$$\mathbf{Catalase}\mathbf{activity}\mathbf{in}\mathbf{unit}/\mathbf{mL} = \frac{\text{[0~sec~OD~} - \ 60\text{Sec~OD]} \times \text{TRV} \times \text{Dilution~factor}}{\text{Efficient~coefficient} \times \text{TSV}}$$Where OD = Optical Density; TRV = Total reaction volume; TSV = Total Sample Volume.

2.7. Histopathological analysis {#sec2.7}
-------------------------------

Microscopic analysis of the tissue was done in order to ascertain the manifestation of the disease. Brain and liver tissue samples were collected from sacrificed zebra fishes and fixed in 10 % neutral buffered formalin solution. Fixed specimen were further dehydrated in different alcohol series, acetone and xylene consecutively before embedding in paraffin. Afterward, paraffin blocks were trimmed and sectioned at 4 μm. Deparaffinization followed by hematoxylin and eosin staining was performed, processed into a thin microscopic section and slides were examined under light microscopy at 400X magnification. Images were further taken for biopsy and pathological examination. Only the histopathological report of the brain sample was given in this study. Image J software was further used for the counting of cells.

2.8. Statistical analysis {#sec2.8}
-------------------------

From data obtained, values are represented as mean ± standard error of mean (SEM). The statistical analysis involving two groups was evaluated using SPSS by means of one-way analysis of variance (ANOVA). Tukey\'s multiple comparison test was used for statistical comparison between Normal control, Disease control, and various treated groups. The homogeneity of the various groups were further analyzed by Tukey\'s post hoc test. Statistical significance was accepted at the ρ \< 0.05 values. Statistical significance was represented as \*, \*\*^,^ and \*\*\* when ρ \< 0.01, ρ \< 0.01 and ρ \< 0.001when compared to diabetic group and ^**\#\#\#**^ when compared to control.

3. Results {#sec3}
==========

3.1. Antidiabetic activity {#sec3.1}
--------------------------

20 mg/kg b*.w* multi-low dose STZ significantly (^\#\#\#^ρ \< 0.001) induced hyperglycemia when compared to normal control as represented in [Table 1](#tbl1){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"}. The plasma glucose increases from 101.56 ± 4.523 mg/dL at day 0--175.87 ± 5.998 mg/dL after the completion of the quarterly administration of STZ on the 28^th^ day with hyperglycemia persisting after second dose of STZ (Day 14). At a Diosgenin concentration of 20mg (DG 1), glucose concentration significantly (\*\*\*ρ \< 0.001) reduced from 186.82 ± 2.451 at a minimum value of 178 and a maximum of 192 to 105.682 ± 4.485 at a minimum and maximum value of 99.76 and 123.45 respectively by the 28^th^ day of treatment. 40 mg/kg Diogenin (DG2) also showed significant (ρ \< 0.01) decrease in the level of plasma glucose at day 14 and an increased significance (\*\*\*ρ \< 0.001) on the 21^st^ and 28^th^ day (190.60 ± 0.892 mg/dL to 116.806 ± 9.183 mg/dL; 90.85 ± 7.796 mg/dL and 82.06 ± 7.270 mg/dL at day 14, Day 21 and day 28 respectively). At 40 mg/kg Diosgenin (DG 2), a minimum and maximum value of 188.23 and 193.27 at day 0 and 59.27 and 101.30 at day 28 were obtained respectively.Table 1Effect of DG on glucose level.Table 1Effect of multi-low dose STZ and DG on glucose concentration of Zebra fishes (n = 5)Glucose Concentration (mg/dL)S/NGroupDay 0Day 7Day 14Day 21Day 28INC96.95 ± 3.7497.19 ± 5.2597.70 ± 3.9998.13 ± 2.7296.62 ± 3.96IIDS101.56 ± 4.52106.68 ± 6.76^\#^156.03 ± 8.62^\#\#\#^173.34 ± 5.32^\#\#\#^175.87 ± 6.00^\#\#\#^IIIDS-BG182.71 ± 3.02179.08 ± 3.63\*\*\*165.05 ± 3.12157.32 ± 5.23148.20 ± 6.95\*IVDS-STD184.17 ± 3.88151.23 ± 2.82134.67 ± 3.28128.41 ± 2.33\*\*\*112.25 ± 5.24\*\*\*VDS-DG1186.82 ± 2.45160.90 ± 5.79\*\*127.32 ± 6.45\*131.65 ± 2.02\*\*\*105.68 ± 4.49\*\*\*VIDS-DG2190.60 ± 0.89139.29 ± 8.59116.81 ± 9.18\*\*90.85 ± 7.80\*\*\*82.06 ± 7.27\*\*\*[^1]Figure 1Effect of STZ and DG on blood glucose level. Data is presented as Mean ± SEM for Normal control (NC), Disease (DS), DS with BG vehicle (DS-BG), DS with positive metformin control (DS-STD), DS with 20 mg/kg diosgenin (DS-DG1) and 40 mg/kg diosgenin (DS-DG2). The significance of each is indicated as \*ρ \< 0.05, \*\*ρ \< 0.01 and \*\*\*ρ \< 0.001 when Disease control (Group II) is compared with Group III, IV, V and VI and ^\#^ρ \< 0.05, ^\#\#^ρ \< 0.01 and ^\#\#\#^ρ \< 0.001 when normal control (Group 1) is compared with Disease (Group 2).Figure 1

3.2. Effect on body weight {#sec3.2}
--------------------------

The changes in body weight of Zebrafishes during disease and different treatment conditions were analyzed for this study. As presented in [Table 2](#tbl2){ref-type="table"}, a continuous increase in weight between day 0 till day 14, followed by a marked reduction in weight of diabetic fishes was observed (i.e Day 0 = 0.336 ± 0.0123 g; Day 7 = 0.387 ± 0.0178 g; Day 14 = 0.396 ± 0.0213 g; Day 21 = 0.341 ± 0.022 g and Day 28 = 0.278 ± 0.0210 g. As compared to the normal control, a significant (^**\#**^p \< 0.05 and ^**\#\#\#**^p \< 0.001) changes in weight of fishes was recorded at day 21 and 28. Diosgenin, (20 and 40 mg/kg) gave a significant (\*\*\*p \< 0.01) increase in body weight of diseased fishes till day 28 from an average weight of 0.286 ± 0.00663 and 0.292 ± 0.00967 at day 0--0.306 ± 0.00368 and 0.3018 ± 0.0110 at day 28 in DG1 and DG2 respectively. BG vehicle shows a slight (\*\*p \< 0.01) increase in weight of zebra fishes at days 7 and 14 with no significant difference in subsequent treatment days ([Figure 2](#fig2){ref-type="fig"}).Table 2Weight changes in Zebrafish with disease and treatment progression.Table 2Effect of multi-low dose STZ (DS) and DG on the weight of Zebra fishesWeight in gS/NGroupDay 0Day 7Day 14Day 21Day 28INC0.338 ± 0.010.340 ± 0.010.343 ± 0.010.347 ± 0.010.358 ± 0.01IIDS0.366 ± 0.010.387 ± 0.02^\#^0.396 ± 0.02^\#^0.341 ± 0.020.278 ± 0.02^\#\#\#^IIIDS-BG0.327 ± 0.010.329 ± 0.02**\*\*\***0.330 ± 0.01**\*\*\***0.330 ± 0.010.332 ± 0.01**\***IVDS-STD0.309 ± 0.01\*\*0.310 ± 0.01\*\*0.311 ± 0.01**\*\***0.312 ± 0.010.313 ± 0.01VDS-DG10.286 ± 0.01\*\*0.288 ± 0.01**\*\*\***0.294 ± 0.01**\*\*\***0.300 ± 0.010.306 ± 0.00VIDS-DG20.292 ± 0.01\*\*0.294 ± 0.01**\*\*\***0.296 ± 0.01**\*\*\***0.300 ± 0.010.302 ± 0.01[^2]Figure 2Changes in weight of ZF with multi-low dose STZ administration and treatment groups. Data is presented as Mean ± SEM for Normal control (NC), Disease (DS), DS with BG vehicle (DS-BG), DS with positive metformin control (DS-STD), DS with 20 mg/kg diosgenin (DS-DG1) and 40 mg/kg diosgenin (DS-DG2). The significance of each is indicated as \*ρ \< 0.05, \*\*ρ \< 0.01 and \*\*\*ρ \< 0.001 when Disease control (Group II) is compared with Group III, IV, V and ^\#^ρ \< 0.05, ^\#\#^ρ \< 0.01 and ^\#\#\#^ρ \< 0.001 when normal control (Group 1) is compared with Disease (Group 2) using ANOVA followed by Tukey\'s test.Figure 2

3.3. Catalase (CAT) {#sec3.3}
-------------------

The catalase activity as a measure of enzymatic catalase antioxidant activity was kinetically determined in response to its ability to consume hydrogen peroxide in the liver ([Table 3](#tbl3){ref-type="table"}) and brain tissues ([Table 4](#tbl4){ref-type="table"}, [Figure 3](#fig3){ref-type="fig"}). The activity of catalase in the liver expressed as unit catalase activity in 1 mL protein (1unit/mL) was shown to significantly (p \< 0.05) reduce from 206.42 ± 30.771unit/mL at day 0--123.85 ± 29.991unit/mL at day 28 at a minimum and maximum value of 103.21 and 275.23 respectively. A significant difference of 13.76 ± 34.872; -82.99 ± 23.884 ρ \< 0.05; -97.68 ± 21.47 ρ \< 0.01; -97.69 ± 29.64 ρ \< 0.05; -110.09 ± 33.93 ρ \< 0.05 was obtained at day 0, 7, 14, 21 and 28 when disease group (DS) was compared with Normal control (NC). Further activity with 20 and 40 mg/kg DG showed significant improvement in catalytic activity but and a more effective activity was observed in DG2 (p \< 0.01). A pronounced significant increase (p \< 0.01) in catalytic activity from a mean activity of 130.73 ± 27.52 unit/mL at a minimum and maximum value 206.42 and 330.28 at day 0 to a mean activity of 255.96 ± 30.34 at a minimum and maximum value of 206.42 and 330.28 at day 28 was shown in DG2. In ZF brain catalytic activity in DS was found to significantly reduce (ρ \< 0.001) from an average of 219.10 ± 7.81 unit/mL at day 0--92.89 ± 32.46 after day 28 of disease induction. Treatment with DG 1 and DG 2 showed a significantly improved elevation from 69.49 ± 14.20 unit/mL (34.40 min/120.40 max value) and 105.28 ± 23.27 (34.40 minimum/151.38 maximum) at day 0 to an average catalytic activity of 112.85 ± 11.01 unit/mL (82.57 minimum/151.38 maximum) and 143.12 ± 33.60 unit/mL (96.33 minimum and 275.23 maximum) at Day 28 ([Figure 3](#fig3){ref-type="fig"}, [Table 4](#tbl3){ref-type="table"}).Table 3Catalytic activity in ZF Liver.Table 3Effect of multi-low dose STZ (DS) and DG on the antioxidant activity of Zebra fishesCatalytic Liver activity in Unit/mLS/NGroupDay 0Day 7Day 14Day 21Day 28INC192.66 ± 31.90220.18 ± 17.54**\***221.19 ± 19.98**\*\***214.75 ± 22.76\*233.94 ± 20.06**\***IIDS206.42 ± 30.77137.19 ± 10.89**\***123.51 ± 8.29**\*\***117.06 ± 16.73**\***123.85 ± 29.99**\***IIIDS + BG106.70 ± 13.80134.86 ± 6.74116.42 ± 7.58235.79 ± 20.30**\*\***295.23 ± 19.02**\*\***IVDS + DG1101.58 ± 11.2979.81 ± 12.6195.31 ± 3.22100.79 ± 8.13130.98 ± 17.13VDS + DG2130.73 ± 27.52123.85 ± 28.20212.92 ± 24.83\*\*214.68 ± 30.34\*255.96 ± 30.34\*\*[^3]Table 4Catalytic activity in ZF Brain.Table 4Effect of multi-low dose STZ (DS) and DG on the antioxidant activity of Zebra fishesCatalytic Brain activity in Unit/mLS/NGroupDay 0Day 7Day 14Day 21Day 28INC259.80 ± 8.89246.46 ± 12.97246.22 ± 12.84259.79 ± 7.03259.79 ± 8.89IIDS219.10 ± 7.81543.58 ± 122.31^**\#**^698.65 ± 65.99^**\#\#\#**^192.66 ± 31.9092.89 ± 32.46^\#\#\#^IIIDS + BG110.09 ± 29.09**\*\***115.83 ± 22.00\*\*\*110.32 ± 30.77**\*\*\***119.72 ± 8.80152.75 ± 13.83IVDS + DG169.49 ± 14.20**\*\***85.32 ± 7.02**\*\*\***89.05 ± 17.87**\*\*\***106.65 ± 14.51112.85 ± 11.01VDS + DG2105.28 ± 23.27**\*\***129.36 ± 7.02**\*\*\***134.86 ± 11.84**\*\*\***148.62 ± 33.00143.12 ± 33.60[^4]Figure 3Catalytic activity of ZF brain with multi-low dose STZ administration and treatment groups is represented herein. Data is presented as Mean ± SEM. The significance of each is indicated as \*p \< 0.05, \*\*p \< 0.01 and \*\*\*p \< 0.001 when Disease control (Group II) is compared with Group III, IV, V and ^\#^p \< 0.05, ^\#\#^p \< 0.01 and ^\#\#\#^p \< 0.001 when normal control (Group 1) is compared with Disease (Group 2) using ANOVA followed by Tukey\'s test.Figure 3Table 5Cell quantification analysis of histopathological photomicrographs.Table 5SliceCell countTotal AreaAverage size% AreaZf-DS 130445841319.197.80Zf-DS 236629170425.049.24Zf-DS + DG120554456315.6855.37Zf-Ds + DG228134978416.6987.17[^5]

3.4. Histopathological analysis {#sec3.4}
-------------------------------

Histology of the brain of zebra fishes is presented in the photomicrographs below ([Figure 4](#fig4){ref-type="fig"}). Microscopic investigation to further identify the structural and morphological transformations exerted by DG and STZ Diabetic ZF at day 21 and 28 ([Figure 4](#fig4){ref-type="fig"}a and b) showed the occurrence of cerebral damage via the tissue degeneration, scattered inflammatory cells, activation of glial cells with increased cell population. After an array of treatment with DG 1 and DG 2 ([Figure 4](#fig4){ref-type="fig"}c and d), the cerebral cortex featured few oligodendrocytes and moderate inflammatory cell infiltrates. Cell quantification and size is also presented in [Table 5](#tbl5){ref-type="table"}, [Figure 6](#fig6){ref-type="fig"} in order to feature the cellular environment. Treatment with STZ at day 21 and 28 ([Figures 5](#fig5){ref-type="fig"}a and 5b) showed an increased cell volume and cellular aggregation was activated at day 28. DG treated groups ([Figures 5](#fig5){ref-type="fig"}c and 5d) of DG1 and DG2 showed a slight difference in the orientation with a decrease in cell volume and size.Figure 4Photomicrographs of histopathological analysis of brain by H&E staining; (A) Diabetic-STZ Dose 3 (B) diabetic-STZ Dose 4, (C) and (D) 20 and 40 mg/kg diosgenin respectively. Arrows: yellow (Astrocytes), green (tissue degeneration of cerebral cortex), orange (glial cells aggregate).Figure 4Figure 5Image analysis showing the number of cells during STZ and DG (DG1 and DG2) treated ZF. Day 21(A) and Day 28 (B) of STZ treatment indicates scattered and increased volume of astrocytes (glial cells GC) with activation of aggregation of GC at day 28 (B). DG 1 (C) and DG2 (C) progressively reduce cell volume as shown in the image.Figure 6

3.5. Behavioral analysis {#sec3.5}
------------------------

The result of Zebra fishes\' behavioral pattern after undergoing a Novel tank diving test (NTT) and Light-dark test (LDT) is presented in Figures [6](#fig6){ref-type="fig"} and [7](#fig7){ref-type="fig"} below. Time spent up and in the light region including a number of transitions up and toward the light region in NTT and LDT are represented in Figures [6](#fig6){ref-type="fig"} and [7](#fig7){ref-type="fig"} below. Result indicated a significant (^\#\#^P \< 0.01) decrease in time spent in the upper region of the tank (NTT) when Diabetic ZF were compared to control ZF after exposure to a multi low dose of STZ (20 mg/kg b*.w*) four times for 28 days (1.567 ± 0.258; df = 1.933; p-value = 0.005) at a 0.5156 and 3.3511 lower and upper bound respectively. After diabetic fishes were treated with diosgenin, time spent in the upper region of the tank significantly elevated (\*\*\*p \< 0.001 and \*\*p \< 0.01) to 4.717 ± 0.309 and 3.567 ± 0.443 at a mean difference (df) of 3.150 and 2.000 in DG1 and DG2 respectively (see [Figure 6](#fig6){ref-type="fig"}). During LDT, Diabetic fishes spent approximately 2.733 ± 0.354 min; (df = 3.117 ± 0.472) in the light region of the tank. In comparison with the control fishes, a significant (^**\#\#\#**^p \< 0.001) decrease in time spent in the light region was observed in Diabetic ZF [(Figure 6)](#fig6){ref-type="fig"}. DG1 and DG2 treated ZF displayed an increased time spent when exposed to LDT test (7.433 ± 0.244 df = 4.70 ± 0.472; 7.900 ± 0.348 df = 5.17 ± 0.472). The number of transitions in diseased ZF is shown in [Figure 7](#fig7){ref-type="fig"}. Diseased fishes displayed number of transition up the tank (5.67 ± 0.333, ^\#\#\#^p \< 0.001) and light region (4.83 ± 0.307, ^**\#\#**^p \< 0.01) as compared to the control fishes (1.83 ± 0.307) at a mean difference of -3.833 (NTT) and -2.00 (LDT) between the control and diseased groups. DG 1 and DG 2 showed significantly fewer transitions in the two tests (NTT and LDT) when compared to disease group (\*\*\*p \< 0.001) but no significant difference was observed between DG1 and DG2. In NTT, a mean transition of 1.83 ± 0.401 and 2.00 ± 0.365 with a mean difference of 3.83 and 3.67 was recorded for DG1 and DG 2 respectively while LDT gave a mean transition number of 1.83 ± 0.307, df = 3.00 and 3.00 ± 0.447 df = 2.83 (see [Figure 7](#fig7){ref-type="fig"}).Figure 6Effect of STZ and DG on the number of time spent in the water surface (NTT) and lit region (LDT) within a maximum of 10 min. The significant difference is represented as ^\#\#^p \< 0.01 and ^\#\#\#^p \< 0.001when disease control is compared with normal control \*\*\*p \< 0.001 when disease is compared with DG 1 and DG 2 using ANOVA followed by Tukey\'s test.Figure 5Figure 7Effect of STZ and DG on the number of time spent in the water surface (NTT) and lit region (LDT) within a maximum of 10 min. The significant difference is represented as ^\#\#^p \< 0.01 and ^\#\#\#^p \< 0.001when disease control is compared with normal control and \*\*\*p \< 0.001 when disease group is compared with DG 1 and DG 2 using ANOVA followed by Tukey\'s test.Figure 7

4. Discussion {#sec4}
=============

Insulin resistance and defective insulin secretion can be linked to the persistent hyperglycaemic state in the pathogenesis of type 2 diabetes mellitus ([@bib16]; [@bib40]). Elevated blood glucose results from impaired insulin secretion from β-cells and a showcase of inadequate compensation for non-insulin sensitivity in peripheral tissue. Also, This condition influences the overproduction of reactive oxygen species (ROS), leading to depleted antioxidant defense capacity, hence, oxidative stress by activating the stress transduction factor pathways ([@bib54]). During these multifactorial complications, behavioral patterns tend to be influenced ([@bib49]), including body weight. The increased ROS triggers non-genetic changes and dysfunctional endothelial cells, thereby, stimulating more ROS production that causes cell instability in cell membrane due to lipid peroxidation, finally leading to inflammation and damage to the affected organs and tissue ([@bib8]; [@bib12]).

Streptozotocin (STZ) is widely known to depict a hyperglycaemic condition due to its ability to directly cause destruction to the pancreatic β-cell, thereby resulting in an inconsistent and impaired insulin production ([@bib44]; [@bib41]). The zebrafish model is developed to elucidate these complications. After the third dose of administration, fishes showed an increased blood glucose concentration with a maximum significance (p \< 0.01) after the last STZ dose as shown in [Table 1](#tbl1){ref-type="table"}. This confirms the development of hyperglycemia related to type 2 diabetes induction by STZ. Diosgenin at a concentration of 20 and 40 mg/kg b.w in Bottle gourd (BG) seed oil as a vehicle decreases the glucose concentration significantly (p \< 0.01) to a mean difference of -27.60 ± 8.174, -70.184 ± 8.174 and -82.490 ± 6.67 for BG, DG1, and DG2 (Group 4, 5 and 6) respectively as compared to the Disease group (Group 2) after 28^th^ day of treatment. This supports the previous report on the blood-glucose-lowering property of Diosgenin due to its alpha-glucosidase inhibitory effect and the presence of B-sitosterol ([@bib33]; [@bib39]; [@bib45]; [@bib11]).

From the studies carried out on body weight, the significant decrease (p \< 0.001) in body weight of ZF after the last dose of STZ indicates an acute induction of diabetes. Elevated loss in body weight in diabetic condition is an indication of a profound breakdown of muscle tissue, protein oxidation, including gluconeogenesis which explains decreased body weight as a metabolic impairment associated with diabetes ([@bib38]). This can also be associated with pancreatic Beta cell damage as reported by [@bib28] ([@bib28]). During treatment, diosgenin and BG oil, decreased body weight was altered. This explains the possibility of Diosgenin in BG oil to promote muscular tissue repair, alter gluconeogenesis and enhance insulin production.

The behavioral pattern of zebra fishes was also studied with disease progression since clinical and pre-clinical data have confirmed the association of diabetes in aggravating the incidence of cognitive decline ([@bib15]), with a possibility of two times likelihood of anxiety and anxiety-like behavior of hyperglycemic history. The NDT and LDT as a robust and relevant measure for anxiety in zebrafish reveals the anxious-like behavior in zebra fishes after the third dose of diosgenin as fishes spent more time at the bottom of the tank with less vertical exploration. Our result confirmed that i.p dose of 20 mg/kg multiple low dose streptozotocin significantly promotes the anxiety-like behavior induced by STZ as reported in a previous study ([@bib23]; [@bib18]). In contrast, Diosgenin attenuates the effect caused by STZ by increasing the number of vertical transitions and time spent on the water surface and lit compartment as reported in our tank diving results and LDT.

Since persistent and prolonged hyperglycemia through inhibition of insulin signal causes increased production of reactive oxygen species and imbalance with antioxidant defense system, oxidative stress becomes elevated. Catalase is an heme-containing ubiquities enzyme that uses up hydrogen peroxide produced by superoxide dismutase during dismutation reaction in order to prevent the generation of hydroxyl radicals responsible for oxidative damage ([@bib26]; [@bib51]). Our result confirmed the reduced activity of catalase enzyme in diabetic fishes. This can be attributed to the high probability of awakening of numerous oxidative stress pathways such as glucose autooxidation, polyol pathway, AGE formation and PKC β ½ Kinase in a hyperglycaemic state ([@bib9]). After the third dose of 40 mg/kg Diosgenin in BGsO, the effect of reactive oxygen species was attenuated by improving the activity of the antioxidants. The ability displayed by diosgenin can be attributed to the body\'s response to reactive oxygen species indicating that diosgenin can revive the antioxidant enzymatic activities owning to the presence of a hydroxyl group in its structural composition ([@bib37]; [@bib2]).

Histopathological studies were carried out to further compensate our studies. Histology of the brain tissues of zebra fishes was studied since critical pathological activities tend to occur in the brain during hyperglycemia and diabetes because of reduced glucose utilization during this period ([@bib34]; [@bib35]). Cerebrovascular inflammation is also reported as one of the major pathophysiological features in diabetes and its vascular complication ([@bib22]; [@bib19]). In our study, Diabetic rats showed cerebral cortex with astrocytes, few oligodendrocytes, hyperglycemia-induced and scattered inflammatory cells in a fibrillary background with very occasional neuron seen at day 21 and severe neuronal loss after the 28^th^ day of STZ administration. Since glial cells are easily influenced by any change or damage in the brain, its activation in terms of cell number and morphology is a significant sign of severe inflammation ([@bib35]). From our histology report of the diabetic brain, aggregation of glial cells was reported as a biomarker indicating severe brain tissue damage. These astrocytes and glial cell activation can be attributed to the hyperglycaemic effect followed by pancreatic β-cell damage, thereby mediating inflammatory pathways and cytotoxic products such as Interleukin-1 (IL-1) and ROS responsible for cerebral damage ([@bib17]; [@bib3]; [@bib46]). [@bib31] reported acute cerebral infarction in the presence of diabetes mellitus ([@bib31]). After the last treatment dose, the section examined showed cerebral cortex with focal densely scattered inflammatory cells in DG1 and moderate inflammatory cells infiltrate in DG2 and Vehicle but with neuronal loss. This shows the potential of DG in improving the pathological features of the damaged brain by altering the neuronal cell death, improving the antioxidant capacity and cerebral function. This means although, activation of microglia is a response to a brain insult such as inflammation and neurotoxins but its overstimulation can promote the already-existing neuronal damage via increased production of neurotoxins. Meanwhile, the neuroprotective effect of diosgenin is presented through its ability to regulate microglial activation as previously reported ([@bib52]). Further image analysis on cell quantification revealed the presence of numerous neuronal cells in diseased ZF with some large cellular globules compared to DG treated ZF groups. This alteration in cell morphology, size and volume is in agreement with a previous study that when the brain is insulted chemically and mechanically, hypertrophy and proliferation is enhanced due to structural and functional changes ([@bib43]). This contributes to neurotoxicity from inflammatory cytokines and free radical with subsequent neuronal damage that severely contributes to the pathogenesis of neurodegenerative disease ([@bib6]; [@bib5]).

In order to assess the diabetic-related behavioral changes in ZF, the NTT and LDT were considered. NTT and LDT have been widely explored and reported as an analog to study stressors, anxiety-like behaviors and drug responses in zebra fishes since the former targets exploration and locomotive pattern of fishes while the latter is capable of displaying the natural tendency of light avoidance and open anxiety-like phenotypes (Scototaxis) in fishes ([@bib48], [@bib47]; [@bib32]; [@bib25]). In our study, time spent up and time spent in the light including the number of transitions up and towards the light region in both NTT and LDT respectively were reported as the endpoint. From our results, diseased ZF showed a much longer avoidance of the water surface as much time was spent at the bottom of the tank. Similarly, diseased fishes showed a high level of light avoidance by spending higher time in the dark region. Further studies towards the number of transition within the scheduled 10 min revealed that diseased fishes transited to the top and to the light region twice as much as the treatment group. This indicated that although diseased fishes spent less time in the light and on the water surface, but they displayed an unrestful state by an increased number of urgent transitions with immediate return. On comparing with the treatment group, DG1 and DG2 significantly increased the time spent in both cases with a decreased number of transitions. The difference in the behavioral pattern of both diseased and treated groups signifies a comparable ground. This unusual behavioral pattern in both groups can be tailored to the influence of diabetic complications in relation to dysfunctional neurobehavior ([@bib7]).

5. Conclusion {#sec5}
=============

Diosgenin selectively lowers the blood glucose concentration in a hyperglycemia-induced diabetes condition. It improves the weight and growth pattern of diabetic zebrafishes and also displayed enhanced catalytic activity. Its activity towards protecting the brain from the possibility of hyperglycemic-mediated brain damage and apoptotic brain cell death is visible from the suppressed inflammation. This study set forth the possibility and potential of diosgenin as an anti-inflammatory and antidiabetic and neuroprotective agent. Its neuroprotectant potential can be positively explored in future clinical studies.
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[^1]: Data is presented as Mean ± SEM for Normal control (NC), Disease (DS), DS with BG vehicle (DS-BG), DS with positive metformin control (DS-STD), DS with 20 mg/kg diosgenin (DS-DG1) and 40 mg/kg diosgenin (DS-DG2). The significance of each is indicated as \*ρ \< 0.05, \*\*ρ \< 0.01 and \*\*\*ρ \< 0.001 when Disease control (Group II) is compared with Group III, IV, V and VI and ^\#^ρ \< 0.05, ^\#\#^ρ \< 0.01 and ^\#\#\#^ρ \< 0.001 when normal control (Group 1) is compared with Disease (Group 2).

[^2]: Data is presented as Mean ± Standard Error of Mean for Normal control (NC), Disease (DS), DS with BG vehicle (DS-BG), DS with positive metformin control (DS-STD), DS with 20 mg/kg diosgenin (DS-DG1) and 40 mg/kg diosgenin (DS-DG2). The significance of each is indicated as \*ρ \< 0.05, \*\*ρ \< 0.01 and \*\*\*ρ \< 0.001 when Disease control (Group II) is compared with Group III, IV, V, VI and ^\#^ρ \< 0.05, ^\#\#^ρ \< 0.01 and ^\#\#\#^ρ \< 0.001 when normal control (Group 1) is compared with Disease (Group 2).

[^3]: Catalytic activity of ZF with multi-low dose STZ administration and treatment groups represented herein. Data is presented as Mean ± SEM for Normal control (NC), Disease (DS), DS with BG vehicle (DS-BG), DS with 20 mg/kg diosgenin (DS-DG1) and 40 mg/kg diosgenin (DS-DG2). The significance of each is indicated as \*ρ \< 0.05, \*\*ρ \< 0.01 and \*\*\*ρ \< 0.001 when Disease control (Group II) is compared with Group III, IV, V and ^\#^ρ \< 0.05, ^\#\#^ρ \< 0.01 and ^\#\#\#^ρ \< 0.001 when normal control (Group 1) is compared with Disease (Group 2) using ANOVA followed by Tukey\'s test.

[^4]: Catalytic activity of ZF Brain with multi-low dose STZ administration and treatment groups represented herein. Data is presented as Mean ± SEM for Normal control (NC), Disease (DS), DS with BG vehicle (DS-BG), DS with 20 mg/kg diosgenin (DS-DG1) and 40 mg/kg diosgenin (DS-DG2). The significance of each is indicated as \*ρ \< 0.05, \*\*ρ \< 0.01 and \*\*\*ρ \< 0.001 when Disease control (Group II) is compared with Group III, IV, V and ^\#^ρ \< 0.05, ^\#\#^ρ \< 0.01 and ^\#\#\#^ρ \< 0.001 when normal control (Group 1) is compared with Disease (Group 2) using ANOVA followed by Tukey\'s test.

[^5]: Table showing the number of cells with their mean size during ZF treatment with STZ and DG (DG1 and DG2). Day 21(A) and Day 28 (B) represents day 21 and 28 of STZ induced T2DM development. The progressive effect of STZ on the number of brain cells and morphology represents Slice Zf-DS1 and ZF-DS2 in the table. ZF-DS1 and ZF-DS2 treatment indicates an increased volume of astrocytes (glial cells GC). ZF-DS + DG1 and ZF-DS + DG2 progressively reduce cell volume and mean size.
